Avai Bio (AVAI) Long-Term Deferred Tax (2023 - 2026)

Avai Bio has disclosed Long-Term Deferred Tax across 4 years of filings, most recently posting $5.9 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 42.48% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (up 42.48% YoY), while the FY2026 annual figure was $5.9 million, up 42.48% from the prior year.
• Long-Term Deferred Tax came in at $5.9 million for Q1 2026 at Avai Bio, up from $4.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $5.9 million in Q1 2026 to a low of $847920.0 in Q1 2023.
• Average Long-Term Deferred Tax over 4 years is $3.5 million, with a median of $3.5 million recorded in 2024.
• Year-over-year, Long-Term Deferred Tax surged 251.02% in 2024 and soared 38.37% in 2025.
• Over 4 years, Long-Term Deferred Tax stood at $847920.0 in 2023, then surged by 251.02% to $3.0 million in 2024, then soared by 38.37% to $4.1 million in 2025, then soared by 42.48% to $5.9 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $5.9 million in Q1 2026, $4.1 million in Q1 2025, and $3.0 million in Q1 2024.